PanFAM-1 is an ongoing prospective validation study for the early diagnosis of pancreatic cancer in high-risk individuals with Familial Pancreatic Cancer (FPC).

PanFAM-1 is now registered on, a web-based registry of clinical trials and the largest clinical trial database in the world. Link to PanFAM-1 on

The study, that was started in December 2016, will analyze more than one thousand high risk individuals over a three-year period, across multiple sites in the US and Europe that are already offering FPC screening programs. To achieve this, a number of collaborations with clinics and research centers with world renowned clinical expertise in pancreatic cancer and a broad patient reach have been established, including Mount Sinai, New YorkKnight Cancer Institute at Oregon Health and Sciences University, Portland, OR; The University of Pittsburgh Medical Center Pittsburgh, PA; The Massachusetts General Hospital, Boston, MANYU School of Medicine, New YorkResearch Institute of the McGill University Health Centre (RI-MUHC), Montreal Canada; The Trustees of the University of Pennsylvania; University of Massachusetts; Yale University MA; University of Chicago Medical Center, IL; Columbia University, New York; The University of Liverpool, UK; University College London (UCL), UKRamon y Cajal Institute for Health Research Madrid, Spain; University Hospital of Santiago de Compostela, Spain, Clínica Universidad de Navarra, Spain, Catalan Institute of Oncology (ICO Hospitalet) – Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, SpainKarolinska Institutet, Stockholm, SwedenSahlgrenska University Hospital, Gothenburg, Sweden, Umeå University Hospital, Sweden and Linköping University Hospital, Sweden. Several other centers are in the process of joining PanFAM-1 study.

The aim is to validate the clinical utility of IMMray™ PanCan-d, proving the overall healthcare benefits of testing familial/hereditary pancreatic cancer patients based on this technology.

IMMray™ PanCan-d is currently undergoing a prospective validation study to confirm our findings before market introduction. We are very interested in getting into contact with high-risk individuals with hereditary pancreatic cancer in the family. For information on eligibility to participate in the US, please contact

In Swedish healthcare, there are guidelines for the treatment of pancreatic cancer. These guidelines have been developed by a group of experts on pancreatic cancer. The guidelines for the care of pancreatic cancer provide guidelines for finding a cancer as early as possible through a targeted screening program. If you are interested in participating in this screening program for individuals with an increased risk of pancreatic cancer, we recommend that you do the following:

1. Contact your healthcare center
2. Ask them to refer you to an investigation at the clinic-genetic unit located at your hospital. The clinical genetic investigation determines if you run sufficiently high risk and thus meet the conditions for participating in the program.

You will also find information about pancreatic cancer and high-risk individuals at the Swedish patient organization PALEMA’s website (information in Swedish)


  1. American Society of Clinical Oncology, ’Pancreatic Cancer: Risk Factors’,
  2. Mouad E, Guido E, ’Risk factors for pancreatic cancer: underlying mechanisms and potential targets’, Front Physiol. 2014; 5: 490.
  3. Theodore B, Anna Mae Diehl, ’Advanced Therapy in Gastroenterology and Liver Disease’, PMPH-USA, 2005, s. 825.


Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports